Abstract Colon-specific drug delivery systems (CDDS) can be used to treat a variety of colon-related issues, including ulcerative colitis, colon cancer, Crohn’s disease, irritable bowel syndrome, and chronic pancreatitis. Many medications used to treat conditions other than colon problems may also be absorbed systemically through the colon. If drugs like proteins and peptides—which are known to disintegrate in the excessive gastric pH—are transported to the colon intact, colonic mucosa can ingest them and absorb them systemically. The intended delivery mechanism must particularly target the colon when administering medications for therapeutic purposes. Colon-targeted medication delivery systems have been developed using a variety of formulation strategies. In order to accomplish colon targeting, these methods use formulation ingredients that interact with one or more features of gastrointestinal (GI) physiology, such as the pH differential along the GI tract, the presence of colonic bacteria, and enzymes. This article emphasizes the factors affecting colon-specific medication delivery, colonic bioavailability, and CDDS limits. Also, the study offers an organized discussion of different traditional as well as comparatively more recent formulation approaches/technologies currently used for the production of CDDS.
Keywords colon targeting drug delivery system, various parameters that affect colon delivery,